^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Enhertu (fam-trastuzumab deruxtecan-nxki) (HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IN VITRO AND IN VIVO EFFICACY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN EPITHELIAL OVARIAN CANCER WITH HER2/NEU OVEREXPRESSION
Published date:
09/08/2022
Excerpt:
KRCH31 and OVA10 EOC cell lines expressed HER2...Apoptotic cells increased to 65% and 60% in the KRCH31 and OVA10 cell lines after T-DXd….T-DXd showed in vitro and in vivo preclinical efficacy in HER2 overexpressing EOC.
